Could vulvar lichen sclerosus progress to skin cancer?

Question

Hello doctor,

I am reaching out regarding my 55-year-old wife, who has been diagnosed with vulvar lichen sclerosus for the past three years. Despite consistent treatment, her condition has progressively worsened.

Initially, she presented with vulvar itching and pain, leading to the diagnosis. Currently, the skin around her vulva appears white and thin, with noticeable scarring. She has been using Clobetasol propionate cream as prescribed; however, the improvement has been minimal. Recently, she has developed painful fissures that bleed, and intercourse has become increasingly difficult, leading her to avoid intimacy altogether.

Our dermatologist has informed us of the increased risk of skin cancer associated with lichen sclerosus. Given her current symptoms and the progression of the condition, we are seeking your expert advice on the following:

How often should she be monitored to assess the progression of the condition and adjust treatment as necessary?
Are there other treatment modalities available beyond topical steroids, especially considering her current response to Clobetasol propionate?

We are committed to managing her condition effectively and would greatly appreciate your guidance on the best course of action.

Please help.

Thank you.

Answer 1

Hi,

Welcome to icliniq.com.

I read your query and can understand your concern.

It appears that your wife's lichen sclerosus has progressed to an advanced stage, which can understandably be concerning. This chronic inflammatory skin disorder, particularly when it affects the vulva, can lead to thinning, scarring, fissures, and significant discomfort. As you have noted, these symptoms are indeed distressing.

The primary treatment for lichen sclerosus involves the application of topical Clobetasol. However, in some cases, patients may require adjusted treatment plans or additional therapies if symptoms persist or worsen.

Here is an overview of key considerations:

Lichen sclerosus carries a slightly increased risk (approximately four to five percent) of developing vulvar squamous cell carcinoma over time. To manage this risk:

Regular monitoring by a dermatologist or gynecologist familiar with the condition is essential, typically every six to 12 months.
Any areas that become thickened, ulcerated, or otherwise suspicious should be biopsied promptly.

Treatment options beyond Clobetasol (a topical corticosteroid used to treat various skin conditions). If Clobetasol is not yielding the desired results, consider the following alternatives:

Tacrolimus ointment: A calcineurin inhibitor that may be effective in steroid-resistant cases.
Platelet-rich plasma (PRP) therapy: Emerging evidence supports its use in severe or refractory cases.
Photodynamic therapy: Less commonly used, but may be beneficial in resistant cases.
Surgical intervention: For symptomatic scarring (example: adhesiolysis, cutting or separating the fibrous bands, surgery to relieve symptoms, and getting the organs working normally again) in select patients, though performed cautiously.

Supportive measures

Use gentle cleansers and avoid irritants such as soaps and tight clothing.
Consider sexual counseling or pelvic floor therapy if intimacy has been affected.
Topical emollients (like Vaseline (petrolatum jelly) or zinc-based ointments) can provide comfort and protect the skin barrier.

This condition can be both physically and emotionally challenging. A multidisciplinary approach, incorporating care from a dermatologist, gynecologist, and possibly a psychosexual therapist, is crucial. With appropriate adjustments and ongoing care, many women experience significant relief and an improved quality of life.

I hope this helps.

Please revert in case of further queries.

Thank you.